Skip to main content
. 2017 Mar 24;72(6):1731–1740. doi: 10.1093/jac/dkx064

Figure 1.

Figure 1

Median (IQR) tenofovir and tenofovir-dp in blood plasma and PBMCs following a single dose of tenofovir alafenamide. Tenofovir over 14 days in plasma (a) and tenofovir-dp in PBMCs (b). Plot inserts depict concentrations over 24 h for each matrix. Concentration values BLQ were imputed at half the LLOQ for graphing purposes. Broken horizontal lines represent the LLOQ. At least 32% of plasma samples had unquantifiable tenofovir and at least 8% of PBMC samples had unquantifiable tenofovir-dp. Percentage of samples that were BLQ at each sampling time is tabulated below each graph. TAF, tenofovir alafenamide.